SB70-AA3,77,23
23“
Section
67. 20.435 (5) (by) of the statutes is repealed.”.
SB70-AA3,78,1
1“
Section
68. 20.435 (5) (cc) of the statutes is created to read:
SB70-AA3,78,32
20.435
(5) (cc)
Youth crisis stabilization facilities; grants. The amounts in the
3schedule for grants under s. 51.042 (3m).”.
SB70-AA3,78,5
5“
Section
69. 46.48 (3m) of the statutes is created to read:
SB70-AA3,78,106
46.48
(3m) Deaf, hard of hearing, and deaf-blind behavioral health
7treatment center. The department may distribute not more than $1,936,000 in
8each fiscal year, beginning in fiscal year 2024-25, to a statewide provider of
9behavioral health treatment services for individuals who are deaf, hard of hearing,
10or deaf-blind.”.
SB70-AA3,78,12
12“
Section
70. 46.48 (31) of the statutes is amended to read:
SB70-AA3,78,1613
46.48
(31) Peer run respite centers. The From the appropriation under s.
1420.435 (5) (bc), the department may distribute
not more than $1,200,000 in each 15fiscal year, beginning in fiscal year 2014-15,
grants to regional peer run respite
16centers for individuals with mental health and substance abuse concerns.”
.
SB70-AA3,78,18
18“
Section
71. 13.48 (26m) of the statutes is created to read:
SB70-AA3,78,2419
13.48
(26m) Lead service line replacement. The legislature finds and
20determines that the prevalence of lead service lines in connections to public water
21systems poses a public health hazard and that processes for reducing lead entering
22drinking water from such pipes requires additional treatment of wastewater. It is
23therefore in the public interest, and it is the public policy of this state, to assist
24private users of public water systems in replacing lead service lines.
SB70-AA3,72
1Section
72. 20.005 (3) (schedule) of the statutes: at the appropriate place,
2insert the following amounts for the purposes indicated:
-
See PDF for table ![PDF](https://docs.legis.wisconsin.gov/assets/image/file_acrobat.gif)
SB70-AA3,73
3Section
73. 20.320 (2) (a) of the statutes is created to read:
SB70-AA3,79,64
20.320
(2) (a)
Lead service line replacement. As a continuing appropriation, the
5amounts in the schedule for lead service line replacement loans under s. 281.61 (8)
6(b).
SB70-AA3,74
7Section
74. 281.61 (8) (b) of the statutes is created to read:
SB70-AA3,79,108
281.61
(8) (b) The department of administration shall allocate the amount
9appropriated under s. 20.320 (2) (a) to projects involving forgivable loans to private
10users of public water systems to replace lead service lines.”.
SB70-AA3,79,12
12“
Section
75. 601.41 (13) of the statutes is created to read:
SB70-AA3,79,1813
601.41
(13) Value-based diabetes medication pilot project. The
14commissioner shall develop a pilot project to direct a pharmacy benefit manager, as
15defined in s. 632.865 (1) (c), and a pharmaceutical manufacturer to create a
16value-based, sole-source arrangement to reduce the costs of prescription medication
17used to treat diabetes. The commissioner may promulgate rules to implement this
18subsection.”.
SB70-AA3,79,20
20“
Section
76. 15.197 (20) of the statutes is created to read:
SB70-AA3,80,3
115.197
(20) Spinal cord injury council. (a) There is created in the department
2of health services a spinal cord injury council that, except as provided in par. (b),
3consists of the following members appointed by the department for 2-year terms:
SB70-AA3,80,54
1. One member representing the University of Wisconsin School of Medicine
5and Public Health.
SB70-AA3,80,66
2. One member representing the Medical College of Wisconsin.
SB70-AA3,80,77
3. One member who has a spinal cord injury.
SB70-AA3,80,88
4. One member who is a family member of a person with a spinal cord injury.
SB70-AA3,80,99
5. One member who is a veteran who has a spinal cord injury.
SB70-AA3,80,1110
6. One member who is a physician specializing in the treatment of spinal cord
11injuries.
SB70-AA3,80,1212
7. One member who is a researcher in the field of neurosurgery.
SB70-AA3,80,1413
8. One member who is a researcher employed by the veterans health
14administration of the U.S. department of veterans affairs.
SB70-AA3,80,1715
(b) If the department of health services is unable to appoint a member specified
16in par. (a) 1. to 8., the department of health services may appoint a member
17representing the general public in lieu of the member so specified.
SB70-AA3,77
18Section
77. 255.45 of the statutes is created to read:
SB70-AA3,80,20
19255.45 Spinal cord injury research grants and symposia. (1)
20Definitions. In this section:
SB70-AA3,80,2121
(a) “Council” means the spinal cord injury council.
SB70-AA3,80,2222
(b) “Grant program” means the program established under sub. (2).
SB70-AA3,81,5
23(2) Grant program. The department shall establish a program to award
24grants, from the appropriation under s. 20.435 (1) (b), to persons in this state for
25research into spinal cord injuries. The purpose of the grants is to support research
1into new and innovative treatments and rehabilitative efforts for the functional
2improvement of people with spinal cord injuries, and research topics may include
3pharmaceutical, medical device, brain stimulus, and rehabilitative approaches and
4techniques. Grant recipients shall agree to present their research findings at
5symposia held by the department under sub. (3).
SB70-AA3,81,8
6(3) Symposia. The department may hold symposia every 2 years for recipients
7of grants under the grant program to present findings of research supported by the
8grants.
SB70-AA3,81,12
9(4) Grant reports. By January 15 of each year, the department shall submit
10an annual report to the appropriate standing committees of the legislature under s.
1113.172 (3) that identifies the recipients of grants under the grant program and the
12purposes for which the grants were used.
SB70-AA3,81,13
13(5) Council. (a) The council shall do all of the following:
SB70-AA3,81,1514
1. Develop criteria for the department to evaluate and award grants under the
15grant program.
SB70-AA3,81,1716
2. Review and make recommendations to the department on applications
17submitted under the grant program.
SB70-AA3,81,1818
3. Perform other duties specified by the department.
SB70-AA3,81,2219
(b) Each member of the council shall disclose in a written statement any
20financial interest in any organization that the council recommends to receive a grant
21under the grant program. The council shall include the written statements with its
22recommendations to the department on grant applications.
SB70-AA3,9119
23Section 9119.
Nonstatutory provisions; Health Services
SB70-AA3,82,3
1(1)
Spinal cord injury council; initial appointments. Notwithstanding the
2length of terms specified for the members of the spinal cord injury council under s.
315.197 (20) (a) (intro.), initial appointments to the council shall be made as follows:
SB70-AA3,82,64
(a) The members appointed under s. 15.197 (20) (a) 1., 3., 5., and 7., or in lieu
5of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on
6July 1, 2025.
SB70-AA3,82,97
(b) The members appointed under s. 15.197 (20) (a) 2., 4., 6., and 8., or in lieu
8of those members under s. 15.197 (20) (b), shall be appointed for terms expiring on
9July 1, 2026.”.
SB70-AA3,82,11
11“
Section
78. 15.07 (3) (bm) 7. of the statutes is created to read:
SB70-AA3,82,1312
15.07
(3) (bm) 7. The prescription drug affordability review board shall meet
13at least 4 times each year.
SB70-AA3,79
14Section
79. 15.735 of the statutes is created to read:
SB70-AA3,82,17
1515.735 Same; attached board. (1) There is created a prescription drug
16affordability review board attached to the office of the commissioner of insurance
17under s. 15.03. The board shall consist of the following members:
SB70-AA3,82,1818
(a) The commissioner of insurance or his or her designee.
SB70-AA3,82,2219
(b) Two members appointed for 4-year terms who represent the
20pharmaceutical drug industry, including pharmaceutical drug manufacturers and
21wholesalers. At least one of the members appointed under this paragraph shall be
22a licensed pharmacist.
SB70-AA3,82,2423
(c) Two members appointed for 4-year terms who represent the health
24insurance industry, including insurers and pharmacy benefit managers.
SB70-AA3,83,3
1(d) Two members appointed for 4-year terms who represent the health care
2industry, including hospitals, physicians, pharmacies, and pharmacists. At least one
3of the members appointed under this paragraph shall be a licensed practitioner.
SB70-AA3,83,54
(e) Two members appointed for 4-year terms who represent the interests of the
5public.
SB70-AA3,83,8
6(2) A member appointed under sub. (1), except for a member appointed under
7sub. (1) (b), may not be an employee of, a board member of, or a consultant to a drug
8manufacturer or trade association for drug manufacturers.
SB70-AA3,83,13
9(3) Any conflict of interest, including any financial or personal association, that
10has the potential to bias or has the appearance of biasing an individual's decision in
11matters related to the board or the conduct of the board's activities shall be
12considered and disclosed when appointing that individual to the board under sub.
13(1).
SB70-AA3,80
14Section
80. Subchapter VI (title) of chapter 601 [precedes 601.78] of the
15statutes is created to read:
SB70-AA3,83,1616
CHAPTER 601
SB70-AA3,83,1817
SUBCHAPTER VI
18
Prescription drug
SB70-AA3,83,1919
affordability review board
SB70-AA3,81
20Section
81. 601.78 of the statutes is created to read:
SB70-AA3,83,21
21601.78 Definitions. In this subchapter:
SB70-AA3,83,23
22(1) “Biologic” means a drug that is produced or distributed in accordance with
23a biologics license application approved under
21 CFR 601.20.
SB70-AA3,83,25
24(2) “Biosimilar” means a drug that is produced or distributed in accordance
25with a biologics license application approved under
42 USC 262 (k) (3).
SB70-AA3,84,2
1(3) “Board” means the prescription drug affordability review board established
2under s. 15.735 (1).
SB70-AA3,84,5
3(4) “Brand name drug” means a drug that is produced or distributed in
4accordance with an original new drug application approved under
21 USC 355 (c),
5other than an authorized generic drug, as defined in
42 CFR 447.502.
SB70-AA3,84,8
6(5) “Financial benefit” includes an honorarium, fee, stock, the value of the stock
7holdings of a member of the board or any immediate family member, and any direct
8financial benefit deriving from the finding of a review conducted under s. 601.79.
SB70-AA3,84,9
9(6) “Generic drug” means any of the following:
SB70-AA3,84,1110
(a) A retail drug that is marketed or distributed in accordance with an
11abbreviated new drug application approved under
21 USC 355 (j).
SB70-AA3,84,1212(b) An authorized generic drug, as defined in
42 CFR 447.502.
SB70-AA3,84,1413
(c) A drug that entered the market prior to 1962 and was not originally
14marketed under a new drug application.
SB70-AA3,84,17
15(7) “Immediate family member” means a spouse, grandparent, parent, sibling,
16child, stepchild, or grandchild or the spouse of a grandparent, parent, sibling, child,
17stepchild, or grandchild.
SB70-AA3,84,18
18(8) “Manufacturer” means an entity that does all of the following:
SB70-AA3,84,2119
(a) Engages in the manufacture of a prescription drug product or enters into
20a lease with another manufacturer to market and distribute a prescription drug
21product under the entity's own name.
SB70-AA3,84,2322
(b) Sets or changes the wholesale acquisition cost of the prescription drug
23product described in par. (a).
SB70-AA3,84,24
24(9) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).
SB70-AA3,85,2
1(10) “Prescription drug product” means a brand name drug, a generic drug, a
2biologic, or a biosimilar.
SB70-AA3,82
3Section
82. 601.785 of the statutes is created to read:
SB70-AA3,85,8
4601.785 Prescription drug affordability review board. (1) Mission. The
5purpose of the board is to protect state residents, the state, local governments, health
6plans, health care providers, pharmacies licensed in this state, and other
7stakeholders of the health care system in this state from the high costs of prescription
8drug products.
SB70-AA3,85,9
9(2) Powers and duties. (a) The board shall do all of the following:
SB70-AA3,85,1210
1. Meet in open session at least 4 times per year to review prescription drug
11product pricing information, except that the chair may cancel or postpone a meeting
12if there is no business to transact.